You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Neurological conditions
  5. Epilepsy

Epilepsies in children, young people and adults

  • NICE guideline
  • Reference number: NG217
  • Published:  27 April 2022
  • Last updated:  30 January 2025
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History
Download guidance (PDF)
  • Overview
  • 1 Diagnosis and assessment of epilepsy
  • 2 Information and support
  • 3 Referral to tertiary specialist services
  • 4 Principles of treatment, safety, monitoring and withdrawal
  • 5 Treating epileptic seizures in children, young people and adults
  • 6 Treating childhood-onset epilepsies
  • 7 Treating status epilepticus, repeated or cluster seizures, and prolonged seizures
  • 8 Non-pharmacological treatments
  • 9 Psychological, neurobehavioural, cognitive and developmental comorbidities in epilepsy
  • 10 Reducing the risk of epilepsy-related death including sudden unexpected death in epilepsy
  • 11 Service provision and transition
  • Terms used in this guideline
  • Recommendations for research
  • Rationale and impact
  • Context
  • Finding more information and committee details
  • Update information

On this page

  1. 10.1 Risk factors
  2. 10.2 Interventions

10 Reducing the risk of epilepsy-related death including sudden unexpected death in epilepsy

10.1 Risk factors

10.1.1

Be aware that epilepsy is associated with an increased risk of premature death, including a risk of sudden unexpected death in epilepsy (SUDEP).

10.1.2

Be aware that potentially modifiable risk factors for SUDEP include:

  • non-adherence to medication

  • alcohol and drug misuse

  • having focal to bilateral tonic-clonic seizures or generalised tonic-clonic seizures

  • having uncontrolled seizures

  • living alone

  • sleeping alone without supervision.

10.1.3

Be aware that the risk of epilepsy-related death is increased in people with:

  • previous brain injury

  • previous central nervous system infection

  • metastatic cancer

  • previous stroke

  • abnormal neurological examination findings.

10.1.4

Discuss with people with epilepsy, and their families and carers if appropriate, their individual risk of epilepsy-related death, including SUDEP, from the time of diagnosis onwards. For young children, this discussion should be with the child's parents or carers. Discussion should include:

  • supporting them to understand the risks of epilepsy-related death, including SUDEP

  • exploring and agreeing ways to reduce the risks.

10.1.5

Discuss the risk of SUDEP with people who have seizures during sleep and, if appropriate, include their families and carers. Provide information on minimising risks, including taking their medication as prescribed.

10.2 Interventions

10.2.1

Discuss the possibility of introducing or increasing night-time supervision, for example, a parent or carer may wish to use a night monitor for people with epilepsy who have seizures during sleep and have been assessed to be at higher risk of epilepsy-related death.

10.2.2

Support people with epilepsy to take their medications as prescribed to reduce seizures. Explain that uncontrolled seizures increase the risk of epilepsy-related death, particularly for people with generalised tonic-clonic seizures or focal to bilateral tonic-clonic seizures. Follow the recommendations in NICE's guideline on medicines adherence.

For a short explanation of why the committee made these recommendations and how they might affect practice, see the rationale and impact section on reducing the risk of epilepsy-related death including sudden unexpected death in epilepsy.

Full details of the evidence and the committee's discussion are in the following evidence reviews:

  • evidence review 17: prediction of death, including SUDEP, in people with epilepsy

  • evidence review 18: modifiable risk factors for epilepsy related mortality

  • evidence review 19: reducing the risk of seizure-related mortality, including SUDEP.


Next page 11 Service provision and transition Previous page 9 Psychological, neurobehavioural, cognitive and developmental comorbidities in epilepsy
Back to top